RS001 / Ruishun Bio - LARVOL DELTA

A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies (clinicaltrials.gov) - P1 | N=13 | Not yet recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd

New P1 trial • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology